Compare RMCO & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMCO | TNXP |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 199.7M |
| IPO Year | 2021 | 2008 |
| Metric | RMCO | TNXP |
|---|---|---|
| Price | $2.83 | $12.83 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.4K | ★ 435.4K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | $4,949,916.00 | ★ $13,107,000.00 |
| Revenue This Year | $209.10 | $558.11 |
| Revenue Next Year | $133.33 | $38.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 513.30 | 29.85 |
| 52 Week Low | $1.74 | $9.40 |
| 52 Week High | $5.00 | $29.19 |
| Indicator | RMCO | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 51.36 |
| Support Level | $2.64 | $11.98 |
| Resistance Level | $3.04 | $13.18 |
| Average True Range (ATR) | 0.22 | 0.68 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 29.52 | 28.00 |
Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.